Stabilized MHC-I aAPC Scaffolds for On-Demand T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current artificial antigen presenting cell (aAPC) scaffolds face challenges in efficiently expanding tumor-reactive T cells due to instability of MHC molecules, inefficient production methods, and lack of specific molecule combinations for optimal T cell expansion, leading to insufficient differentiation and functional capacity, and are not suitable for high-throughput production.
Innovation Solution
The development of aAPC scaffolds with a polymeric backbone and stabilized MHC class I molecules, featuring a disulfide bridge between alpha-1 and alpha-2 domains, which can be loaded with antigenic peptides on demand, combined with T cell affecting molecules like cytokines and co-stimulatory molecules, to enhance T cell expansion and functional stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MHC molecules are used in conventional aAPC scaffolds, then T cell activation and expansion can be achieved, but the MHC molecules are unstable and prone to aggregation, leading to insufficient production efficiency and functional capacity
Solution Approach 1:
The patent introduces a disulfide bridge between the alpha-1 and alpha-2 domains of the MHC class I molecule, changing the structural parameters to enhance stability. This covalent crosslinking prevents aggregation and maintains proper folding, directly resolving the stability issue while enabling higher production yields of functional aAPCs
Solution Approach 2:
The patent creates a composite structure by combining the MHC class I heavy chain with a disulfide bridge crosslinking mechanism. This composite approach integrates structural reinforcement into the MHC molecule itself, improving reliability without compromising productivity
2Quantity of substance
If extensive ex vivo culturing is performed to expand tumor-reactive T cells, then T cell numbers increase, but T cell differentiation and functional capacity are compromised
Solution Approach 1:
The patent incorporates all necessary T cell affecting molecules (co-stimulatory molecules, cytokines, adhesion molecules) into the aAPC scaffold before T cell expansion. This preliminary configuration of the microenvironment enables efficient T cell expansion while maintaining functional capacity, eliminating the need for extensive culturing that would otherwise compromise T cell quality
Solution Approach 2:
The aAPC scaffold serves multiple functions simultaneously: presenting antigen via stabilized MHC molecules, providing co-stimulation through B7 molecules, delivering cytokine signals, and enabling adhesion. This multi-functionality in a single platform achieves both T cell expansion and functional preservation that would otherwise require separate, extensive culturing steps
3Adaptability or versatility
If multiple MHC class I molecules with different antigenic peptides are produced separately, then antigen specificity can be optimized, but production time and complexity increase significantly
Solution Approach 1:
The patent stabilizes the MHC class I heavy chain structure in advance using a disulfide bridge, creating a pre-configured stable platform that can subsequently bind different antigenic peptides. This preliminary stabilization eliminates the need for separate production and optimization processes for each peptide-MHC combination, dramatically reducing production time while maintaining antigen specificity
Solution Approach 2:
The patent separates the MHC class I molecule into its heavy chain component (which provides structural stability) and the antigenic peptide component (which provides specificity). The stable heavy chain can be produced once and then combined with different peptides, enabling rapid generation of multiple antigen-specific aAPCs without repeating the entire production process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a high-throughput, user-friendly platform for producing a diverse library of aAPCs, ensuring high antigen specificity and functionality of expanded T cells, suitable for tumor regression or viral clearance, with optimized phenotypic and functional properties.
Implementation Method 1
MHC class I molecules stabilised by a disulfide bridge connecting the alpha-1 and alpha-2 domains
Data Source
AI summary
The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise stabilized MHC class I molecules free of antigenic peptide. The scaffolds can be loaded with antigenic peptide on demand, providing an agile platform for effective expansion and functional stimulation of specific T cells in a peptide-MHC-directed fashion.